DuraSite

DuraSite®

Ophthalmology A sustained-release system designed to permit the gradual release of a drug into the eye over a period of hrs, overcoming problems common with conventional drug delivery
References in periodicals archive ?
Ophthalmologic company InSite Vision (Other OTC:INSV) reported on Wednesday the receipt of the US Patent Number 8,778,999 covering Bromfenac Non-Steroidal Ophthalmic Compositions Formulated in DuraSite from the US Patent and Trademark Office (USPTO).
ISV-401 combines azithromycin with DuraSite, the company's patented drug-delivery vehicle that offers the benefits of prolonged release of an active ingredient.
The DuraSite and DuraSite 2 drug delivery systems extend the duration of drug retention on the surface of the eye, thereby reducing the frequency of treatment and improving the efficacy of topical drugs.
According to the company, DexaSite is an investigational product that combines a low dose of the corticosteroid dexamethasone with its proprietary DuraSite drug delivery platform.
This study enrolled more than 240 patients undergoing cataract surgery in a two-arm trial designed to evaluate the efficacy and safety of BromSite against the DuraSite vehicle alone.
Ophthalmic products company Senju Pharmaceutical Co revealed on Tuesday the launch of a collaboration and license agreement to develop and market InSite Vision's (Other OTC:INSV) azithromycin ophthalmic solution using DuraSite including AzaSite 1% and AzaSite Xtra 2% ocular antibiotics in Japan.
Prior clinical trials of BromSite demonstrated superiority over the then market-leader, with twice the tissue penetration using a lower dose of bromfenac due to its formulation in our proprietary DuraSite vehicle.
M2 EQUITYBITES-June 5, 2014-InSite Vision awarded USPTO's Notice of Allowance for Bromfenac formulations in DuraSite, BromSite, ISV-101 & BromDex
M2 PHARMA-June 5, 2014-InSite Vision awarded USPTO's Notice of Allowance for Bromfenac formulations in DuraSite, BromSite, ISV-101 & BromDex
In addition, we debuted our new DuraSite 2 ophthalmic drug delivery platform, which is designed to significantly enhance the duration of drug retention on the eye.
075%) of the non-steroidal anti-inflammatory drug (NSAID) bromfenac with its DuraSite drug delivery technology.
InSite Vision is advancing new ophthalmic products for unmet eye care needs based on its innovative DuraSite([R]) and DuraSite 2[R] platform technologies.